Recent developments include leadership updates, financial results showing fluctuating losses, product certifications, government contracts, and new product launches across subsidiaries.

• Astrotech updated indemnification and leadership arrangements in February 2026 [N1].
• Q2 2026 financial results showed a reduction in net loss compared to prior periods [N2].
• Full year 2025 results reported an increase in net loss compared to the previous year [N3].
• Jennifer Cañas was appointed Chief Financial Officer in May 2025 [N4].
• Q3 Fiscal Year 2025 financial results and product development milestones were reported in May 2025 [N5].
• The enhanced TRACER 1000 Narcotics Trace Detector was launched in March 2025 to address synthetic drug detection [N6].
• EN-SCAN, Inc. was launched in February 2025 to develop environmental testing solutions [N7].
• Q2 Fiscal Year 2025 financial results and developments were reported in February 2025 [N8].

Astrotech’s proprietary AMS Technology platform underpins a diversified portfolio of subsidiaries targeting multiple high-demand markets including security, agriculture, industrial process control, and environmental testing. The TRACER 1000™ has achieved key certifications and government contracts, supporting adoption in airports, cargo hubs, and law enforcement globally. The company’s technology offers advantages in detection accuracy and false alarm reduction compared to incumbent ion mobility spectrometry devices. AgLAB’s mass spectrometry solutions address a growing hemp and cannabis market with demonstrated yield improvements. EN-SCAN’s portable environmental testing instruments provide real-time contamination detection capabilities. The company’s strong liquidity position as of June 2026 supports ongoing development and commercialization efforts. Recent leadership appointments and indemnification updates indicate active corporate governance.

Astrotech has incurred significant losses since inception and continues to report net losses, requiring additional capital to fund operations and product development. The company faces risks related to its ability to raise capital on acceptable terms, which could lead to scaling back or discontinuing product development, relinquishing technology rights, or ceasing operations. The Lunar Initiatives are in very early exploratory stages with no commercial operations or finalized plans, representing uncertain and potentially costly ventures. The company’s common stock faces risks of delisting from Nasdaq due to market value and listing requirements, which could reduce liquidity and capital raising ability. Competition in target markets is intense, and regulatory approvals and market adoption remain challenges. The company’s financial performance and market acceptance of its products remain uncertain.

Astrotech’s moat is based on its proprietary Astrotech Mass Spectrometer Technology™ platform, which offers advantages over traditional mass spectrometry and ion mobility spectrometry technologies by operating under ultra-high vacuum to reduce false positives and provide higher resolution detection. The company holds multiple patents and extensive trade secrets protecting its intellectual property. Its technology is licensed exclusively to its subsidiaries, which develop specialized products for distinct markets such as security screening, agriculture, industrial process control, and environmental testing. The TRACER 1000™ explosives trace detector is certified by European and U.S. authorities, providing regulatory barriers to entry. The company’s ability to expand its threat detection library without degrading performance differentiates it from competitors relying on ion mobility spectrometry. However, the company operates in competitive and evolving markets with regulatory and technological challenges.

• Capital Raising Risk: The company has incurred significant losses and requires additional financing to continue operations and product development. Failure to raise capital on acceptable terms could force scaling back or discontinuation of development, asset disposals, or bankruptcy.
• Nasdaq Listing Risk: Astrotech’s common stock faces potential delisting from Nasdaq due to market value and listing requirements, which could materially reduce liquidity, investor confidence, and ability to raise capital.
• Early-Stage Lunar Initiatives Risk: The Lunar Power and Light Corporation initiatives are exploratory with no commercial operations, technical validation, or financing commitments, exposing the company to high technical, financial, and operational risks.
• Market and Regulatory Risks: The company operates in competitive markets requiring regulatory approvals and customer adoption. Delays or failures in certification, market acceptance, or competition could adversely affect business prospects.

• Astrotech Corporation (Nasdaq: ASTC) is a Delaware corporation organized in 1984 focused on commercializing the Astrotech Mass Spectrometer Technology™ (AMS Technology) platform through application-specific wholly owned subsidiaries [S1].
• AMS Technology is designed to be smaller, less expensive, and easier to use than traditional mass spectrometers, operating under ultra-high vacuum to reduce false alarms and improve resolution [S1].
• Astrotech's subsidiaries include: 1st Detect Corporation (explosives and narcotics trace detectors for security applications), AgLAB Inc. (mass spectrometers for hemp and cannabis industry), BreathTech Corporation (breath analysis for volatile organic compounds), Pro-Control Inc. (industrial process control applications), EN-SCAN Inc. (environmental testing and monitoring solutions), and Lunar Power and Light Corporation (early-stage lunar infrastructure initiatives) [S1].
• 1st Detect has developed the TRACER 1000™, the first MS-based explosives trace detector certified by the European Civil Aviation Conference (ECAC) and approved by the U.S. TSA for air cargo, with deployments in approximately 37 locations across 16 countries as of March 31, 2026 [S1].
• The TRACER 1000 has an extensive and expandable threat detection library, designed to reduce false positives compared to ion mobility spectrometry (IMS)-based ETDs [S1].
• 1st Detect's TRACER 1000 ETD and NTD are listed on the U.S. General Services Administration IT Schedule 70, enabling sales to the U.S. federal government [S1].
• In January 2025, 1st Detect was awarded a DHS contract to develop next-generation explosives trace detection technology [N3][S1].
• In March 2025, Astrotech launched an enhanced TRACER 1000 Narcotics Trace Detector to address synthetic opiates and novel psychoactive substances [N6].
• In April 2025, Astrotech fulfilled a $429,000 purchase order for TRACER 1000 ETDs from a TSA-approved contractor, marking the first TSA-approved sale of this technology [N3][S1].
• In June 2025, the first deployment of the TRACER 1000 Narcotic Trace Detector occurred in Vietnam, expanding presence in Southeast Asia [N3].
• In May 2026, the TRACER 1000 system achieved ECAC/EU G1 approval, meeting the highest European aviation security standards [N5].
• AgLAB develops mass spectrometers for the hemp and cannabis markets, focusing on optimizing yields in distillation processes using the AgLAB 1000-D2™ and Maximum Value Process (MVP) solution, which has demonstrated yield improvements of approximately 15% to 30% in field trials [S1][N5].
• AgLAB has a master lease agreement with SC Laboratories for joint marketing of its products to SC Labs' clients [S1].
• BreathTech developed the BreathTest-1000™ for breath analysis of volatile organic compounds indicating compromised health conditions; however, commercialization requires significant investment and regulatory approval, leading to a strategic focus on other subsidiaries [S1].
• Pro-Control applies AMS Technology for industrial process control in chemical distillation outside agriculture, offering the Pro-Control 1000-D2™ mass spectrometer and Maximum Value Processing to improve reaction intermediates, purity, and yields [S1].
• EN-SCAN produces rugged, portable gas chromatography-based environmental testing instruments for real-time on-site air, water, and soil analysis, with plans to incorporate mass spectrometry in future products [S1][N7].
• Lunar Power and Light Corporation is an early-stage strategic initiative focused on lunar resource development, advanced computing, semiconductor manufacturing, and infrastructure on the Moon; currently exploratory with no commercial operations or finalized plans [S1].
• As of June 30, 2026, Astrotech reported cash and cash equivalents of $8.39 million, current assets of $15.93 million, current liabilities of $2.26 million, resulting in a current ratio of 7.06 and cash ratio of 5.29, indicating strong liquidity [S1].
• For fiscal year ended June 30, 2026, the company reported net income loss of $14.43 million and basic EPS of -$8.49 per share [S1].
• The company has incurred significant losses since inception and anticipates continued losses, requiring additional capital raising to fund operations and product development [S2].
• Astrotech's common stock is listed on Nasdaq Capital Market but faces risks of delisting due to market value and listing requirements, which could adversely affect liquidity and capital raising [S2].
• Recent leadership update includes appointment of Jennifer Cañas as Chief Financial Officer in May 2025 [N4].
• Recent news includes updates on indemnification and leadership arrangements in February 2026 [N1].
• Q2 2026 results showed a reduction in loss compared to prior periods [N2].
• Full year 2025 results showed an increase in loss compared to prior year [N3].